292 related articles for article (PubMed ID: 21675777)
1. New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Zaid AN; Saponaro G; Tabrizi MA; Baraldi S; Romagnoli R; Moorman AR; Varani K; Cosconati S; Di Maro S; Marinelli L; Novellino E; Borea PA
J Med Chem; 2011 Jul; 54(14):5205-20. PubMed ID: 21675777
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
3. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
Baraldi PG; Baraldi S; Saponaro G; Preti D; Romagnoli R; Piccagli L; Cavalli A; Recanatini M; Moorman AR; Zaid AN; Varani K; Borea PA; Tabrizi MA
J Med Chem; 2012 Jan; 55(2):797-811. PubMed ID: 22148859
[TBL] [Abstract][Full Text] [Related]
4. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
[TBL] [Abstract][Full Text] [Related]
5. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Preti D; Tabrizi MA; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Merighi S; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(14):4697-701. PubMed ID: 16000006
[TBL] [Abstract][Full Text] [Related]
6. Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A₃ adenosine receptor antagonists.
Baraldi PG; Saponaro G; Romagnoli R; Aghazadeh Tabrizi M; Baraldi S; Moorman AR; Cosconati S; Di Maro S; Marinelli L; Gessi S; Merighi S; Varani K; Borea PA; Preti D
J Med Chem; 2012 Jun; 55(11):5380-90. PubMed ID: 22568637
[TBL] [Abstract][Full Text] [Related]
7. The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists.
Poli D; Catarzi D; Colotta V; Varano F; Filacchioni G; Daniele S; Trincavelli L; Martini C; Paoletta S; Moro S
J Med Chem; 2011 Apr; 54(7):2102-13. PubMed ID: 21401121
[TBL] [Abstract][Full Text] [Related]
8. Selective human adenosine A3 antagonists based on pyrido[2,1-f]purine-2,4-diones: novel features of hA3 antagonist binding.
Priego EM; Pérez-Pérez MJ; von Frijtag Drabbe Kuenzel JK; de Vries H; Ijzerman AP; Camarasa MJ; Martín-Santamaría S
ChemMedChem; 2008 Jan; 3(1):111-9. PubMed ID: 18000937
[TBL] [Abstract][Full Text] [Related]
9. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.
Yaziji V; Rodríguez D; Gutiérrez-de-Terán H; Coelho A; Caamaño O; García-Mera X; Brea J; Loza MI; Cadavid MI; Sotelo E
J Med Chem; 2011 Jan; 54(2):457-71. PubMed ID: 21186795
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterisation and inhibitory effects of (2R,3R,4S,5R)-2-(6-amino-2-{[(1S)-2-hydroxy-1-(phenylmethyl)ethyl]amino}-9H-purin-9-yl)-5-(2-ethyl-2H-tetrazol-5-yl)tetrahydro-3,4-furandiol, a novel ligand that demonstrates both adenosine A(2A) receptor agonist and adenosine A(3) receptor antagonist activity.
Bevan N; Butchers PR; Cousins R; Coates J; Edgar EV; Morrison V; Sheehan MJ; Reeves J; Wilson DJ
Eur J Pharmacol; 2007 Jun; 564(1-3):219-25. PubMed ID: 17382926
[TBL] [Abstract][Full Text] [Related]
12. 1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.
Colotta V; Catarzi D; Varano F; Calabri FR; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Deflorian F; Moro S
J Med Chem; 2004 Jul; 47(14):3580-90. PubMed ID: 15214785
[TBL] [Abstract][Full Text] [Related]
13. 1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor.
Stefanachi A; Brea JM; Cadavid MI; Centeno NB; Esteve C; Loza MI; Martinez A; Nieto R; Raviña E; Sanz F; Segarra V; Sotelo E; Vidal B; Carotti A
Bioorg Med Chem; 2008 Mar; 16(6):2852-69. PubMed ID: 18226909
[TBL] [Abstract][Full Text] [Related]
14. Expression, pharmacological profile, and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells using a novel selective antagonist radioligand, [3H]MRE 2029-F20.
Gessi S; Varani K; Merighi S; Cattabriga E; Pancaldi C; Szabadkai Y; Rizzuto R; Klotz KN; Leung E; Mac Lennan S; Baraldi PG; Borea PA
Mol Pharmacol; 2005 Jun; 67(6):2137-47. PubMed ID: 15788741
[TBL] [Abstract][Full Text] [Related]
15. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Minetti P; Tinti MO; Carminati P; Castorina M; Di Cesare MA; Di Serio S; Gallo G; Ghirardi O; Giorgi F; Giorgi L; Piersanti G; Bartoccini F; Tarzia G
J Med Chem; 2005 Nov; 48(22):6887-96. PubMed ID: 16250647
[TBL] [Abstract][Full Text] [Related]
16. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
[TBL] [Abstract][Full Text] [Related]
17. 1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.
Fernández F; Caamaño O; Isabel Nieto M; López C; García-Mera X; Stefanachi A; Nicolotti O; Isabel Loza M; Brea J; Esteve C; Segarra V; Vidal B; Carotti A
Bioorg Med Chem; 2009 May; 17(10):3618-29. PubMed ID: 19398343
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors.
Varani K; Gessi S; Merighi S; Vincenzi F; Cattabriga E; Benini A; Klotz KN; Baraldi PG; Tabrizi MA; Lennan SM; Leung E; Borea PA
Biochem Pharmacol; 2005 Nov; 70(11):1601-12. PubMed ID: 16219300
[TBL] [Abstract][Full Text] [Related]
19. N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor.
Volpini R; Dal Ben D; Lambertucci C; Taffi S; Vittori S; Klotz KN; Cristalli G
J Med Chem; 2007 Mar; 50(6):1222-30. PubMed ID: 17309246
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.
Drabczyńska A; Yuzlenko O; Köse M; Paskaleva M; Schiedel AC; Karolak-Wojciechowska J; Handzlik J; Karcz T; Kuder K; Müller CE; Kieć-Kononowicz K
Eur J Med Chem; 2011 Sep; 46(9):3590-607. PubMed ID: 21664729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
